Andrew Bird with puppets !
P.S : Don't forget, on january 21 (this sunday ),on Jack's Big Music Show on Noggin : Andrew Bird, as Dr Stringz, at 12pm ET.
This is a show for children , with puppets ,and this episode features string instruments and the many different ways to play them; The goal is to make music more interactive for children.
Did anyone catch this or YouTube it? COULD anyone? We don't get "Jack's Big Music Show" where I'm at.
My husband taped this and wondered if he should try to make a video for You Tube, but with the Noggin thing we doubted it would be legal with copyrights and everything. It really was a great episode. My niece and nephew like it. The song is very good too.
legal schmegal! Post that puppy!!!!!
Did anyone catch this or YouTube it?
yes, someone did , just go to You Tube , search for Jack's Big Music Show , and enjoy, while it's still possible !
Anyone have the link to that video? I can't seem to find it.... Is it gone already?
I can't help imagining the kids watching this show. In fifteen years, they'll make a search for who was that "wonderful Dr. Stringz" that still lives in their children's memories... What a surprise to discover he made serveral albums.
Andrew Bird's popularity is now assured for the future generation.
yay !!! this is just too cute !!!
that's the best thing in the world!
That's actually how I got into Rufus Wainwright. I was really into this movie "Tommy Tricker and the Stamp Traveller," and when we looked at it later, the name popped out (he played a rock 'n' roll kid in the 6th grade) and I looked into his albums...In the movie he played a song in a concert in a mall during a chase scene.
Sujet: Re: Andrew Bird with puppets !


text:
School of HSHP clinics operate amid COVID-19 pandemic
Bec Legato/The Ithacan
Junior McKensie Galusha, a physical therapy student, treats a patient at the Ithaca College Physical Therapy Clinic in the Center for Health Sciences. The physical therapy clinic, among others, has opened for limited in-person operations for Spring 2021.
By Makayla Carozzolo — Contributing Writer
Although clinics within the School of Health Sciences and Human Performance (HSHP) at Ithaca College are emptier and have fewer patients and staff than previous years, clinical students are still working to get hands-on experiences and assist the community.
The Sir Alexander Ewing-Ithaca College Speech and Hearing Clinic is currently offering in-person service only to the hearing portion of the clinic. These audiology clients can also receive service through teletherapy and curbside service. Speech-language pathology services are being offered remotely through telepractice. The Occupational and Physical Therapy Clinic (OT/PT Clinic) is also offering in-person and telepractice services this semester. The clinicians can work hands-on with patients while wearing safety gear like gloves, face shields, goggles and masks.
In the fall semester, the clinics mostly operated through telepractice, except for the PT clinic, which treated a fellow student–clinician and a staff member in person. The college held classes primarily remotely for Fall 2020, but some students were allowed on campus for the PT Boot Camp.
In addition to telepractice, Amie Germain, assistant professor in the Department of Occupational Therapy and OT/PT Clinic faculty member, said the OT clinic held virtual therapy sessions with families through Zoom for students to learn how to engage with children in an online setting.
Chris McNamara, clinical associate professor and clinic director of the Department of Physical Therapy, said that in the fall, both PT and OT students did case study-based learning scenarios. These are published cases of patients or made-up cases that allow students to work through the mechanics of developing a care plan.
First-year physical therapy graduate student Tayo Akinboboye, a student–clinician, said the OT/PT Clinic opened Jan. 25. Akinboboye said that when the clinic opened, he and the other student–clinicians learned about the rules and started working in the clinic. Akinboboye said that by Feb. 1, they had their first client.
McNamara said the OT/PT Clinic is open to approved on-campus college community members, and patients must complete the daily health screening to access the clinic. She said the clinic is currently not treating pediatric patients in person because they are typically accompanied by parents or siblings, and the clinic cannot fit additional people due to lowered room capacity.
The clinic is not treating individuals with neurological impairments face-to-face either because these individuals usually have more of a complex health status and are being treated remotely instead, McNamara said. The clinic is also not currently treating Longview residents, who have typically received treatment at the clinic, in person. The college and Longview have been partnered for over 20 years, but this semester the partnership is operating remotely.
The hearing clinic opened in person Feb. 8. Amy Rominger, clinical associate professor in the Department of Speech-Language Pathology and Audiology, said the in-person services are only offered to community members who are approved to access the campus. Patients have to complete the daily health screening provided by the college and answer additional health questions prior to their arrival.
Patients must wear masks during appointments, and clinicians must wear masks, gloves and face shields, Rominger said. In addition to the new safety equipment, the hearing clinic no longer reuses supplies.
"This is where infection control and budget concerns always come to play," she said. "Anything that was multi-use before is now single use as far as supplies go, with the exception, certainly, of the actual equipment that we have. We just disinfect and sanitize that."
First-year occupational therapy graduate student Jessica Freeborn said similar protective gear is worn in the OT/PT Clinic. She said OT student–clinicians wear masks and goggles and remain socially distant from each other and patients.
Akinboboye said the PT students wear the same protective gear with the option to wear a face shield instead of goggles and gloves depending on whether the clinician or client wants them.
The hearing clinic is operating with fewer student–clinicians at once. Rominger said that previously, she would have two student–clinicians with her at all times. She said that due to the lower patient population they are seeing this semester and wanting to rotate student–clinicians for a week or two each, only one student–clinician is working with Rominger at a time.
First-year speech-language pathology graduate student Kate Quigley worked in the hearing clinic for the first time Feb. 18. She said she had one hour of direct client contact, and she was able to administer a hearing evaluation to a client.
She said that this semester each student–clinician will have approximately three clients and work five to six hours per week through telepractice and in-person work combined.
McNamara said the OT/PT Clinic is not using its waiting room this semester and has gone paperless to protect clients and clinicians. She said the PT clinic is having students mostly work in pods of four and occasionally in pairs. McNamara said the clinic's goal is to have each student work with one patient.
Germain said the OT student–clinicians are working in smaller groups than PT due to the density requirements of the OT rooms.
Freeborn said she is working with one other student in the OT clinic.
"That's been working well," Freeborn said. "It's a very personalized experience, so we can just bounce ideas off each other and just have more of a personal aspect to therapy. We just treat one client together."
Student–clinicians who are working in person at the hearing and OT/PT clinics are eligible to get the COVID-19 vaccine. McNamara said that Christina Moylan, director of Public Health Emergency Preparedness at the college, worked directly with the Tompkins County Health Department and the Cayuga Health System to submit a list of which groups at the college would need the vaccine including the student–clinicians working in the clinics. In New York state, health care workers are considered a "priority group" eligible for the vaccine.
Quigley said it was exciting to be in the clinic and to get in-person experience. She said she believes every proper safety protocol is being followed.
"I felt 100% comfortable," Quigley said. "Of course I wanted to make sure the client also felt comfortable because there were some things that we had to get closer to the client than others, so it's all about the client's preference. But with the proper protocols we have in place, I felt really safe, and I didn't really have much concern."
Akinboboye said he has enjoyed his experience working in the clinic, and he appreciates the interpersonal relationships between PT, OT and speech-language pathology students.
Freeborn said she values the opportunity that working in the OT clinic provides.
"Personally, I think that it's a great experience, especially because a lot of the OT students will be going on their first round of clinicals or fieldwork experiences at the end of March," Freeborn said. "For me it's like a really great way to kind of get my toes wet and see what this might be like when I go on fieldwork, whether it's telehealth or different protocols with sanitization or [personal protective equipment] and how treating clients and in person or face-to-face might look different."
HSHP clinic provides treatment to performers
By Antonio Ferme | Oct 23, 2019
IC community members receive COVID-19 vaccines
By Alyshia Korba | Feb 20, 2021
School of HSHP hosts discussion series about COVID-19 impact
By Luke Haworth | Nov 24, 2020
HSHP clinicsIthaca College Department of Occupational TherapyIthaca College Department of Physical TherapyIthaca College School of Health Sciences and Human PerformanceSir Alexander Ewing-Ithaca College Speech and Hearing Clinic

redpajama_set_name: RedPajamaCommonCrawl


Diamond Delight offers diamond jewelry including rings, earring, necklaces and more. Make use of Diamond Delight Promo Code or coupon code to save your order with discount coupon.
Wide range of high quality Women's Wedding Rings. Shop now for it!
Beautiful Gift WRAPPING at Diamond Delight. Shop now!
Diamond Delight Coupon: 30 Day Hassle FREE Returns. Shop now!
Save 10% OFF All Products with Diamond Delight Promo Code. Shop now!
Save 5% OFF on all products with Diamond Delight Promo Code. Shop now!
Get $3 OFF + FREE Shipping with Email Sign-Up at Body Candy.
Get Up to 80% OFF on Clearance Items with code at My Jewelry Box.
Enjoy FREE USA Shipping on orders over $75 at Pictures On Gold.
Get FREE Shipping on orders of $100 or more at Loveivy. No coupon code needed!
Get 50% OFF Lumos Leather & Crystal Wrap at Joseph Nogucci.
Get 15% OFF First Orders by Joining Email List at Lulu Frost.


text:
Q: Unable to redirect to Lazy Loaded module as default route/url on server start up Good day folks,
I am having this issue in my Angular 2 application upon server startup (npm start).
I redirect the base route or base path to user/login which is a Lazy Loaded module but it throws an Cannot find module error. This always happens as I've said, during startup and editing the pathMatch argument from 'full' to 'prefix' and vice versa fixes the error and loads the route without error.
I hope you can help me with this.
Below is the program.
app/routes.ts
import { Routes } from '@angular/router';
import { AppComponent } from './app.component';

export const appRoutes:Routes = [
    { path: 'user', loadChildren:  'user/user.module#UserModule'},
    { path: '', redirectTo: 'user/login', pathMatch: 'full'}
]

app/app.module.ts
import { NgModule } from '@angular/core';
import { BrowserModule } from '@angular/platform-browser';
import { RouterModule, Routes } from '@angular/router';

import { AppComponent } from './app.component';
import { appRoutes } from './routes';

@NgModule({
declarations: [
    AppComponent
],
imports: [
    BrowserModule,
    RouterModule.forRoot(appRoutes)
],
providers: [],
bootstrap: [AppComponent]
})
export class AppModule { }

app/user/user.routes.ts
import { LoginComponent } from "./login.component";

export const userRoutes = [
    { path: 'login', component: LoginComponent }
]

app/user/user.module.ts
import { NgModule } from "@angular/core";
import { CommonModule } from "@angular/common";
import { RouterModule } from "@angular/router";

import { userRoutes } from "./user.routes";
import { LoginComponent } from "./login.component";

@NgModule({
imports: [
    CommonModule,
    RouterModule.forChild(userRoutes)
],
declarations: [
    LoginComponent
],
providers: [UserAuthService]
})

export class UserModule {}

I hope I've provided enough information about my problem. If not, just let me know. Thank you.
EDIT:
I'm having the same error when I visit user/login upon startup.

A: Edit:
Since Angular 8, the way to lazy load modules is using dynamic imports such as:
 export const appRoutes:Routes = [
    { path: 'user', loadChildren:  () => import('path-to-module').then(m => m.UserModule)},
    { path: '', redirectTo: 'user', pathMatch: 'full'}
]

The accepted answer is not the correct way to implement lazyLoading at all.
This should be the routing mechanism:
app.routes.ts
export const appRoutes:Routes = [
{ path: 'user', loadChildren:  'user/user.module#UserModule'},
{ path: '', redirectTo: 'user', pathMatch: 'full'}

]
user.routes.ts
export const userRoutes = [
 {
path: '',
children: [
  { path: '', redirectTo: 'login', pathMatch: 'full' },
  {
    path: 'login',
    component: LoginComponent
  }]

}
]
ibenjelloun's answer is correct. Since you mentioned somehow it doesn't seem to work for you, I have given an alternative way with child routes.

A: The () => notation actually worked for me. Below is my code regarding how I fixed it just by editing my routes.ts file
app/routes.ts
import { UserModule } from './user/user.module';

export const appRoutes:Routes = [
  { path: 'user', loadChildren: () => UserModule},
  { path: 'login', component: LoginComponent},
  { path: '', redirectTo: 'user/login', pathMatch: 'full'}
]

A: Try changing your user.module.ts like this :
@NgModule({
imports: [
    CommonModule,
    RouterModule.forChild(userRoutes)
],
declarations: [
    LoginComponent
],
exports: [RouterModule], // Add this line
providers: [UserAuthService]
})

export class UserModule {}

And routes.ts :
export const appRoutes:Routes = [
    { path: 'user', loadChildren:  'user/user.module#UserModule'},
    { path: '', redirectTo: 'user', pathMatch: 'full'}
]

Also user.routes.ts :
export const userRoutes = [
    { path: '', redirectTo: 'login', pathMatch: 'full'},
    { path: 'login', component: LoginComponent }
]

A: In case your user has a home component, this trick worked for me :
app.routes.ts
export const appRoutes:Routes = [
  { path: '', redirectTo: 'user', pathMatch: 'full' }
  { path: 'user', loadChildren: () => import('path-to-module').then(m => m.UserModule) }
]

user.routes.ts
export const userRoutes = [{
    path: '',
    component: UserComponent,
    children: [ {
        path:'',
        redirectTo: 'login',
        pathMatch: 'full'
      }, {
        path: 'login',
        component: LoginComponent
      }, {
        path: 'register',
        component: RegisterComponent
    }]
   }
 ]

redpajama_set_name: RedPajamaStackExchange


text:
Congress tied Ukraine military assistance to 'improvement in transparency, accountability… for purposes of decreasing corruption'
Nov. 19, 2019, Fairfax, Va.—Americans for Limited Government President Rick Manning today issued the following statement noting that Congress explicitly tied military assistance to Ukraine to Defense Department certifications that Ukraine is showing "improvement in transparency, accountability… for purposes of decreasing corruption":
"The President is fully within his Article II foreign affairs to reconsider the U.S. relationship with Ukraine, including whether providing military assistance there is consistent with U.S. interests. Under law, the Ukrainian military assistance is explicitly linked to certifications that Ukraine is showing 'improvement in transparency, accountability… for purposes of decreasing corruption.' Given Congress' specific requirements related to corruption, it is clear that even if President Trump had tied military assistance to action by Ukraine on corruption, and wished to roll back prior certifications made, it would have been more than consistent with the law. The fact that he did not exposes the Pelosi-Schiff impeachment as nothing more than a sham."
Interview Availability: Please contact Americans for Limited Government at 703-383-0880 ext. 1 or at media@limitgov.org to arrange an interview.


Do you enjoy the variety that comes with working on multiple projects but want to invest your skills and experience in one award-winning employer?
We are currently recruiting for a Site Manager with both residential and commercial construction experience.
As Site Manager, you will be responsible for the day to day site and safety supervision of the construction project and will report directly to the Project Manager. You will be required to undertake various roles in the project phase and will be flexible and able to work on a variety of projects.
As Site Manager, you will have superior people management and problem-solving skills to lead a site-based team of employees and subcontractors.
The successful candidate will understand and communicate the requirements of project drawings and specifications, manage the subcontracted members of the project team, coordinate delivery, and storage of materials, and constantly review all aspects of the construction against the plan.
As the successful candidate, you ideally have 3 or more years of construction industry experience, preferably from a Tier 1-2 Construction Company and worked on projects from $2 million above.


To make sure that you stay healthy all year round, don't forget to get your health checked regularly. As Singapore's healthcare costs are known to be relatively high, it is essential to choose a comprehensive health insurance that will cover all your medical expenses. Contact one of our advisers today to learn more about your insurance solutions.
Thanks to its privileged location in Asia Pacific, Singapore is only a few hours away from many Asian countries, allowing its residents to travel across the region on many occasions.


text:
Q: Solve for $x$ in $\log_4{(x+4)} \le \log_2{(2x+5)}$
I would like to solve  $$\log_4{(x+4)} \le \log_2{(2x+5)}$$ for $x$.

I did:
$$\log_4{(x+4)} \le \log_2{(2x+5)} \Leftrightarrow \frac{\log(x+4)}{\log(4)} \le \frac{\log(2x+5)}{\log(2)}\\ \Leftrightarrow \frac{\log(x+4)}{2\log(2)} \le \frac{\log(2x+5)}{\log(2)} \Leftrightarrow \frac{1}{2} \cdot \frac{\log(x+4)}{\log(2)} \le \frac{\log(2x+5)}{\log(2)} \Leftrightarrow\ ???$$
What do I do next?

A: Since the following identity holds for all $u>0$:
$$
  \log_{2}\left(u\right) = 2 \log_{4}\left(u\right) = \log_{4}\left(u^2\right)
$$
The original inequality $\log_{4}\left(x+4\right) \leqslant \log_{2}\left(2 x + 5\right)$ can be rewritten as $$\log_{4}\left(x+4\right) \leqslant \log_{4}\left(\left(2 x + 5\right)^2 \right)$$
Since $\log_{4}\left(u\right)$ is an increasing function for $u>0$, this implies
$$
    x + 4 \leqslant \left(2 x+5\right)^2
$$
which has to be supplemented with auxiliary conditions $x+4 > 0$ and $2 x+5 > 0$. This results in the answer
$$
    x \geqslant - \frac{7}{4}
$$

A: Hint: Use that $\log(2)>0$ and that $t\mapsto \log(t)$ and $t\mapsto e^t$ are monotonic functions to continue:
\begin{align}
\frac{1}{2} \cdot \frac{\log(x+4)}{\log(2)} \le \frac{\log(2x+5)}{\log(2)} &\iff \frac{1}{2}\log(x+4) \le \log(2x+5) \\ &\iff \log(\sqrt{x+4}) \le \log(2x+5) \\ &\iff \sqrt{x+4} \leq 2x+5\\ &\iff \ldots\end{align}

A: Remove the common denominator $\log 2$ and multiply by $2$ to clear the fractions.  Thus
$\log(x+4)\leq 2 \log(2x+5)$.
The right side of the above is also $\log((2x+5)^2)$ from the properties of logarithms, so we are reduced to the inequality
$x+4\leq (2x+5)^2$
which can be handled by ordinary algebraic methods (which I leave to the questioner or reader).  You must limit the solution set to a subset of $x > (-(5/2))$ because the logarithms (for real arithmetic) are defined only for positive arguments.


.. in the future, I'll probably change the URL to http://exon.gatech.edu/LHS89, but not until there's been a reasonable show of interest.
I stumbled across your entry while checking to see if there were any WWW servers with info about Lexington and have followed a number of links at your site and am impressed. I understand that you are on the Townwide Educational Technology Committee, as well you should be.
In any event, I wanted to ask you if you'd consider placing a link to the LHS Class of '89 page on your site somewhere. Perhaps some of my old classmates will stumble across it in their net.travels.
One more thing... If I can offer any sort of support to your committee in anyway, please let me know. I am currently working on my PhD in biology her e at Tech and will likely be here for another couple of years. I'm also the sys-admin for this cluster of SPARCStations and the webmaster for them.


text:
Posted in New York Theater, outdoor theater, Theater Reviews
Seven Deadly Sins Review. Thrilling Theater in the Streets of the Meatpacking District
Author: New York Theater Published Date: June 29, 2021 Leave a Comment on Seven Deadly Sins Review. Thrilling Theater in the Streets of the Meatpacking District
Lust was the best. Everybody seemed to agree, and it wasn't just because Cynthia Nixon was in the cast. But, in truth, none of the eight short plays by some of America's most original playwrights are what is most thrilling about "The Seven Deadly Sins," the site-specific theatrical anthology taking place in makeshift storefronts and outdoor stages in the Meatpacking District. What's most exciting is that the audience members could watch them (and discuss them) together, live and in person.
Shuga Cain as the Mistress of Ceremonies in Purgatory from Seven Deadly Sins
Morgan McGhee as 'Naked' and Shavanna Calder as 'Clothed' in Tell Me Everything You Know (inspired by Gluttony) from Seven Deadly Sins.
Cody Sloan as 'Guru' and Bianca Norwood as 'Comments' in Wild Pride (inspired by Pride) from Seven Deadly Sins. Photo by Matthew Murphy.
Shamika Cotton as 'Sandra' and Brandon J. Ellis as 'Jeff' in Hard (inspired by Sloth) from Seven Deadly Sins.
Caitlin O'Connell as 'Madame' and Andrew Keenan-Bolger as 'Philippe' in Naples (inspired by Envy) from Seven Deadly Sins.
Brad Fleischer as 'M' and Kahyun Kim as 'F' in Longhorn (inspired by Wrath) from Seven Deadly Sins.
Tricia Alexandro as 'Vivian' and Eric Ulloa as 'Leo' in Watch (inspired by Greed) from Seven Deadly Sins.
"Isn't it good to be out of the house?" Shuga Cain said to us sweetly, in the first play, "Purgatory," as the 60 of us sat in rows of folding chairs in front of a makeshift stage on Gansevoort Street, across from the Whitney Museum. We were wearing headphones, as Shuga (the drag name of Jesus Martinez Jr, who was a "fan favorite" in Rupaul's Drag Race 11thseason), first lip-synced to "I Feel a Sin Comin' On" by the girl band Pistol Annies, stripping off her nun's habit to reveal a flashy and then explained her personal philosophy about sin (as scripted by playwright Jeffrey LaHoste and Moisés Kaufman, the artistic director of Tectonic Theater Project, and the director of all eight plays):
"'Sinning' is just the old way of saying human nature. After all, if you think about it, all sins arise from love. Envy arises from the love of what others have, gluttony comes from the distorted love of food, lust from the greedy love of carnal pleasures! See…. And since human beings were born to love, maybe we were born to sin too. "
(This made me wonder. If love inspires the seven sins, what causes the seven virtues — prudence, justice, temperance, courage, faith, hope and charity — and will the Tectonic Theater Project and Madison Wells Live produce a sequel, or would there be no market for that?)
One might infer from Shuga's monologue that there would be a consistent theme and tone to the seven two-character plays that followed. But as we were split up into three groups of about 20 theatergoers apiece, and led to each of the plays in random order, it became clear that the tone and the quality of the scripts vary widely. What tied them all together was the consistency of the acting and of David Rockwell's gorgeous set designs and Dede Ayite's costumes, as well as the communal experience of traveling from sin to sin.
First up, arrayed side by side on Gansevoort Street, were Gluttony, Pride and Sloth – the signs above each storefront window advertised the sins, although each play has a specific title (which you can dig up in the digital program.)
"Tell Me Everything You Know" by Ngozi Anyanwu reworks the Biblical story of Eve and the apple, in a confusingly loose definition of gluttony, with Morgan McGhee as the Eve-like character, eager to take a bite of Shavanna Calder's apple, with predictable results.
In "Wild Pride" by MJ Kaufman, Cody Sloan portrays a trans man who has made himself into a YouTube "guru," who sells pride (sometimes literally: "check out my Workouts for Embodied pride series.") His pep talks and advice to his queer or questioning followers (all portrayed by Bianca Norwood) leadeth to their fall. This makes the Guru concede that "sometimes showing our pride costs us." It's a brave and witty, if over-busy unmasking of one of the LGBT community's most sacred buzzwords (during Pride Month no less!), and ends with the perfect punch line.
In "Hard," by Thomas Bradshaw, Sandra (Shamika Cott) tries to get her fat, lazy husband Jeff (a pitch-perfect Brandon J. Ellis) to have sex with her, but he's too busy playing a multi-player video game. That the play becomes increasingly graphic should surprise nobody who knows Bradshaw's work, but it's also funny and, as outlandish as it is, pointed.
After we watched those three plays, our guide led us to 13th Street, narrating the history of the Meatmarket district along the way, pointing out the sites of the former sex clubs, to highlight how apt the location of these plays.
In Ming Pfeiffer's "Longhorn," the pretend-violence of Asian-American dominatrix (Kahyun Kim) and client (Brad Fleischer) turns into something more real and more menacing – hooking, a bit too glibly, into what's been happening in our country.
"Naples" by Jeffrey LaHoste takes place in the Palace of Versailles around 1700, involving the aging Princess Charlotte (Caitlin O'Connell) scheming against her husband's young lover, Philippe (Andrew Keenan-Bolger), which seems less clearly about envy, than lust, or revenge (the latter admittedly not officially a sin.), but in any case it seems an odd fit for a boxy stage in the middle of 13th Street in Manhattan, even though it's still paved with cobblestones.
In Moisés Kaufman's clever, funny "Watch," Leo (Eric Ulloa) and his sister Vivian (standout Tricia Alexandro) are attending their father's funeral, but Leo is aghast and outraged that his father had left instructions with the undertaker to bury him with his $233,000 Rolex watch. There is a twisty end that I should have seen coming, but what's most delightful about this play is Vivian's interaction with a series of (unseen, unheard) mourners, in which we don't have to work hard to imagine their side of the conversation ("37. Not married. No boyfriend. I have a job…")
And finally we come to "Lust" by Bess Wohl, the most unusual and the most rewarding of the plays. To passersby, it would not look like a play at all, just pole dancing, albeit in a storefront rather than a strip club. And indeed, Donna Carnow's bio describes her as "a Brooklyn-based pole dancer, movement artist, choreographer, teacher, performer, pole champion, and aerialist." But here where the headphones come into play (which in most of the plays I found just a necessary inconvenience, and the device even conked out on me a couple of times.) While she's dancing, we hear her thoughts, voiced by Cynthia Nixon – a dazzling monologue that mixes to-do lists, reminiscences, imagined conversations with her kid, complaints about her back…until she spots somebody who has come into the club, and then suddenly we're thrust into her sense of urgency, fear, and alarm, leading us to feel (without completely understanding) the mix of lust and violence that is a mark of modern society.
Indeed, although several of the pieces in "Seven Deadly Sins" deserve similar credit, Wohl's "Lust" is the most effective at translating into modern times the real-life consequences of a so-called cardinal sin (a vice that leads to even worse behavior), a concept that many people these days — certainly many of the New Yorkers drawn to the Meatpacking District for dinner and a show– would dismiss as something quaint and ancient.
Seven Deadly Sins is performing three times a night (except Mondays) through July 25.
Running time: approximately two hours
← Harry Potter and The Boss Back on Broadway! But Off Broadway etc Ain't Chopped Liver! #Stageworthy News of the Week
Theater Quiz for June 2021 →


text:
Филиппинская операция:

 Филиппинская операция (1941—1942) — военная операция Второй мировой войны, произошедшая на Тихоокеанском театре военных действий в 1941—1942 годах.
 Филиппинская операция (1944—1945) — военная операция Второй мировой войны, произошедшая на Тихоокеанском театре военных действий в 1944—1945 годах.

См. также
 Битва при Марианских островах

redpajama_set_name: RedPajamaWikipedia


text:
Posts published in "Joe Biden"
The Jews now dumping Trump won't ever apologize for backing him
By chavurah on January 11, 2021
There were Jews who joined the pro-Trump assault on the Capitol, arm-in-arm with open antisemites. But while most Jewish Trump voters won't mourn his exit,…
How Georgia's glorious Black-Jewish alliance triumphed over the pro-Trump mob
By chavurah on January 7, 2021
The hypocrisy and mayhem of the mob invasion of the Capitol is the critical issue of the moment. The historic Georgia runoff results should be…
Silence in the face of demolition and pogroms
As pro-Trump extremists converge on D.C., will there be 'bloody civil war' or more bluster?
Crowds and white power: As pro-Trump conspiracy theorists, Constitutionally-challenged conservatives, COVID deniers and armed far right gangs prepare to march on the Capitol, is violence…
China is the Middle East's rising power. Israel must tread carefully
By chavurah on December 29, 2020
China can't substitute for American support for Israel. But with Beijing fortifying its position in the Middle East, Israel must engage – or risk its…
How Trump transformed 'quid pro quo' from Democratic slur to diplomatic triumph
The U.S.-brokered Morocco-Israel normalization deal is yet more proof that Trump's much-derided transactional foreign policy actually works. The quid pro quo is good for America,…
Biden's good news for the Jews: A president who will fight America's antisemites, not flatter them
By chavurah on December 9, 2020
The number of antisemitic incidents, which skyrocketed under Trump, won't plummet overnight. But Biden's response will be starkly different from his predecessor's equivocation and selective…
Forget a comprehensive Iran deal. It's an illusion
The danger of Biden wanting an Iran deal too much
A return to the old nuclear deal is a non-starter, writes CUFI's policy head: Any agreement with the Tehran regime must be comprehensive, bipartisan and…
Israeli politics are moving in the opposite direction to America: the demographics play to the right. A Biden-style victory could simply never happen here Source:…
Iran, Biden and the bomb: Why Tehran is now speeding up its nuclear program
Iran has delivered its first real response to Joe Biden's victory, announcing plans for a major escalation in its nuclear program. It's a step-by-step guide…
The desperate campaign to tar Biden as 'anti-Israel'
You might think Biden's lengthy pro-Israel record would inoculate, or at least modestly protect him from the overwrought, vituperative 'Israel-hater' hyperbole thrown at Obama. You'd…
Killing Iran's nuclear weapons chief was justified. But it wasn't wise
By chavurah on November 30, 2020
When Israel weighed up the targeted killing of Mohsen Fakhrizadeh, there are ten criteria it should have considered. Instead it appears that Netanyahu chose a…
Assassinations and sanctions aren't working: Why America and Israel need a new Iran strategy
There's a better way for Biden and Israel to contain Iran's regional meddling and its nuclear aspirations – with the added benefit of clipping the…
The end of the age of politics
'Pro-Israel': How a term hijacked by the right could decide who controls the U.S. Senate
The slurs against Democratic candidates in Georgia's election runoffs are the perfect showcase for how Trump and Netanyahu have twisted what 'pro-Israel' means, and why…
Why Israel should normalize ties with Qatar next
Ties with Qatar would not necessarily be at the expense of Israeli relations with the United Arab Emirates and Saudi Arabia Source: https://www.haaretz.com
No, you do not have to feel the Trump voter's pain
There is no reason, after five and half years of untruths, dog-whistles, slurs and conspiracies, and weeks of Trump trying to undermine Biden's win, to…
No, you don't have to feel the pain of the Trump voter
Trump's 'stolen election' fiction boosts antisemitic extremists. So do Democrats' conspiracy theories
From Trump's QAnon-fueled fiction, to Douglas Macgregor's 'Jews buy support for Israel,' to Marjorie Taylor Greene's 'Zionist supremacist genocide,' the GOP has a toxic antisemitic…


Couples cannot be happy if there are any disturbances in marriage relationship. Disturbance may come from their own quarrels, family members, and other partners in their life. These kind of situations will lead to marriage separation and then divorce. According to Hindu mythology divorce is a very delicate and sensitive issue. I want to suggest you that prevention is better than cure and get prevented by the astrological powers and mantras to save yourself from any future effects in your life. Pandit Vishnu Verma astrology gives best solution for divores cases. Pandit Pandit Vishnu Verma can help you unite or get separated from your partner but you should be clear in what are you looking for. Pandit Pandit Vishnu Verma will also guide you in tensed and disturbed situations.


text:
Facebook hits 2B user milestone - Mobile World Live
HomeAppsNews
Facebook hits 2B user milestone
Facebook now has 2 billion users, hitting the number less than five years after reaching the 1 billion mark.
"We're making progress connecting the world, and now let's bring the world closer together," CEO Mark Zuckerberg said in a post.
On average, each day more than 175 million people share a 'love' reaction and over 800 million people 'like' something on Facebook, and every month more than 1 billion people use Groups, Mike Nowak, product director and Guillermo Spiller, product manager, wrote in a separate post.
They added that Facebook will be sharing several personalised experiences over the coming days to show appreciation for the many ways people support one another on Facebook.
"We are excited to continue to build products that allow people to connect with one another, regardless of where they live or what language they speak."
YouTube is the only other social media platform that comes close to the 2 billion figure, with 1.5 billion users. The only other platforms that have 1 billion users are Facebook's own properties (WhatsApp and Messenger) while Instagram is getting there, with 700 million users currently.
In comparison, WeChat has around 889 million users and Twitter has 328 million.
According to TechCrunch, the developing world has played a big role in Facebook's growth, as the social media giant launched a 'lite' version of its app that works on low-bandwidth connections.
Facebook added 746 million users in Asia and the 'rest of world' region in the past five years but only 41 million in the US and Canada.
The report added that Facebook's current user growth is at 17 per cent, which is as fast or faster than any year since 2012, while 66 per cent of its monthly users return each day now compared to 55 per cent give years ago.
Previous ArticleChina Mobile targets 17% VoLTE penetration this year
Next ArticleInterview: ZTE leads 5G innovation
Saleha Riaz
Saleha joined Mobile World Live in October 2014 as a reporter and works across all e-newsletters - creating content, writing blogs and reports as well as conducting feature interviews...More
Meta tipped to axe thousands of staff
Game over for Facebook Gaming app
UK demands Meta Giphy sale
Get Our Apps Newsletter


In this engaging talk, Jolene Park shares her experience of gray area drinking — the kind of drinking where there's no rock bottom, but you drink as a way to manage anxiety and then regret how much and how often you drink. Regardless of the cause of anxiety or discomfort in your life, and regardless of whether you're using alcohol or another substance or behavior as an attempt to manage stress, Jolene uses her expertise as a Functional Nutritionist to explain the importance of replenishing your neurotransmitters in a comprehensive and consistent way, especially if you want to get off the stopping and restarting drinking merry-go-round.
Jolene Park is the founder of Healthy Discoveries — a corporate wellness company that provides coaching and training programs for high achieving business professionals who struggle with anxiety, stress and gray area drinking. She provides inspirational and empowering approaches for purpose-driven companies and business professionals to create a healthy body, mind and spirit in order to build a deeper internal zone of resilience and well-being. Jolene Park is a functional nutritionist, health coach and stress reduction yoga instructor who works with professional women who struggle with anxiety, perfectionism, and the gray area of drinking. She is the co-host of "Editing Our Drinking & Our Lives" podcast, an honest conversation about breaking the stigma and shame around quitting drinking. Jolene provides an inspirational, empowering way for women to come together and be part of a revolutionary health movement that reclaims their body, mind and spirit.
Through her company Healthy Discoveries — a corporate wellness training and consulting company, Jolene also helps purpose driven companies and business professionals break through barriers and create richer, deeper community and connection as a result.


text:
import re
import requests
from django.core.management.base import BaseCommand
from osf.models import Registration
from website import settings
import logging
from django.db.models import F

logger = logging.getLogger(__name__)

class IAMetadataError(Exception):
    def __init__(self, message=None, fields=None):
        self.message = message
        self.fields = fields

get_ia_field = lambda field: Registration.IA_MAPPED_NAMES.get(field, field)

mirrored_attrs = list(Registration.SYNCED_WITH_IA)

mirrored_fields = mirrored_attrs + ['subjects', 'tags', 'affiliated_institutions']
mirrored_relationships = [
    'subjects__text',
    'affiliated_institutions__name',
    'tags__name',
]

def check_ia_metadata(collection=settings.IA_ROOT_COLLECTION, guids=None):
    item_data = requests.get(
        f'https://archive.org/advancedsearch.php'
        f'?q=collection%3A({collection}) AND identifier:(osf-registrations-*-{settings.ID_VERSION})'
        f'&fl[]='
        + f'&fl[]='.join([get_ia_field(field) for field in mirrored_fields])
        + f'&fl[]=identifier'
        f'&rows=100000'
        f'&output=json'
    ).json()['response']['docs']
    item_data = sorted(item_data, key=lambda x: x['identifier'])

    archived_registrations = Registration.objects.filter(ia_url__isnull=False).exclude(ia_url='').order_by(
        '-ia_url',
    )

    if guids:
        archived_registrations = archived_registrations.filter(guids___id__in=guids)
        item_data = [
            item
            for item in item_data
            if [re.match(guid, item['identifier']) for guid in guids]
        ]

    registration_data = archived_registrations.values(
        *mirrored_attrs,
        'ia_url',
    ).annotate(
        subjects=F('subjects__text'),
        affiliated_institutions=F('affiliated_institutions__name'),
        tags=F('tags__name'),
    )

    if archived_registrations.count() != len(item_data):
        raise IAMetadataError(
            message=f' We have {archived_registrations.count()} registrations with IA urls, but there are'
            f' {len(item_data)} IA items with our id in our collection'
        )

    desynced = {}
    for ia_item, osf_registration in zip(item_data, registration_data):
        for field, osf_value in osf_registration.items():
            ia_url = osf_registration['ia_url']
            ia_value = ia_item.get(Registration.IA_MAPPED_NAMES.get(field, field), None)
            if osf_value != ia_value and field not in (
                'ia_url',
                'modified',
                'moderation_state',
            ):
                if not desynced.get(ia_url):
                    desynced[ia_url] = {'fields': []}
                desynced[ia_url]['fields'].append(field)

    if desynced:
        raise IAMetadataError(fields=desynced, message='some fields weren\'t synced')

class Command(BaseCommand):
    '''
    Checks all IA items in collection to see if they are synced with the OSF
    '''

    def add_arguments(self, parser):
        super(Command, self).add_arguments(parser)
        parser.add_argument(
            '--collection',
            type=str,
            action='store',
            dest='ia_collection',
            help='The Internet Archive collection that we are checking for parity',
        )

    def handle(self, *args, **options):
        collection = options.get('collection', settings.IA_ROOT_COLLECTION)
        check_ia_metadata(collection)

redpajama_set_name: RedPajamaGithub


KGET news Couple Wins Landmark Trial Against Implanted Surgical Mesh Company.
Each of you who blatantly disregarded your patients pain and suffering has broken the oath, "First, Do NO Harm." You have harmed us many times over. And will continue to do so until you take the time to educate yourselves beyond what a pharmaceutical representative tells you.
What, exactly, did you KNOW about mesh before you advised your patient? Did you KNOW that is supposed to be permanent? Did you KNOW that mesh might not work well for everyone? Did you KNOW that mesh was inert, or that it wasn't? Did you KNOW if mesh could shrink, curl and damage surrounding tissue as it moved? Did you KNOW if the patient would have a foreign body response to the mesh? Did you KNOW that a bad reaction might cause repeated infections and or bleeding? Did you KNOW what the possible complications were associated with blind insertion of mesh? Did you KNOW if the one-size-fits-all kits would work on every one the same, regardless of body type or size? Did you KNOW that nerve entrapment or injury was probable? Did you KNOW that if an adverse reaction to mesh occurred that the only way to alleviate the symptoms was to remove the mesh? Did you KNOW that the resulting pain of nerve injury and or reaction to the mesh would cause your patient to LOSE quality of life? Did you KNOW how many of your patients might die due to complications arising from mesh implantation? Did YOU know?
If you didn't you should have. If you did, you forgot to mention this to us. Failing to tell us any of that, how could you belittle us when we begged for help? Is there something written somewhere that this is due course when a patient comes to you for medical assistance? We came to you, as a person of trust, to help us find answers to why we were left in this horrible condition after an operation you claimed would lift our quality of life.
Instead of answers we had pieces of eroding mesh yanked and cut from our most private parts without any numbing agents. Then we were sent to pain clinics where we were given painful shots in our abdomens and sensitive pelvic areas, that gave little to no relief, and pelvic physical therapists who caused more pain. And when these actions didn't alleviate our symptoms we asked if the mesh was the cause. Our question was not appreciated which resulted in our being disrespected, treated to eye rolls and told it was all in our head. In some cases you walked out on us, told us to leave or were physically and or verbally abusive. Yet many of us continued to believe in you even though, in our hearts, we knew different and have suffered needlessly because of it.
Many, if not all of us, have been told we were the "only" patient who ever had problems. How can hundreds, thousands, tens of thousands (the total numbers are unknown) of people each be the ONLY one who has had adverse reactions to mesh? How many complications were you aware of but didn't bother to mention because you were told they were rare and this was the GOLD STANDARD of treatment for POP, SUI and Hernia repair?
If you are finding many more patients than usual do not trust your advice it is because you have forced us to look beyond you, to look for answers you are either unwilling or unable to give. YOU are the doctor, the one who is supposed to know the medical answers and if you don't then it is your job to find them.
It is not the patients responsibility to determine whether a product or drug is in their best interest, to know what is safe. That is YOUR responsibility, why you get paid the big bucks! Just because a representative of a pharmaceutical company says it's so, doesn't make it so. And just because the FDA has cleared a product through the 510(k) doesn't mean that it's safe for patient use. It's time to go back to treating patients as human beings instead of quotas on the insurance gravy train .
. and if you can't or won't then maybe it's time for a new career.
Regina Holliday keynotes in Australia!
A 'patient harm' advocate keynotes in Australia!
Regina Holliday is a young mother of two sons who is tirelessly working to make sure that all patients have access to their medical record. Her husband's death was fraught with medical missteps and gaffs that were hurtful and altogether preventable. It is her mission that these health system errors are corrected.
She is now in Sydney, Australia to keynote the Health Informatics Conference.
While she is working for us, let us overwhelm her with donations to her favorite causes!
Provide travel/conference cost support for patients and their advocates.
Metal on metal hips have harmed thousands. June 27and 28, 2012, FDA allowed each harmed patient just 4 minutes to testify. Patients paid for their own flights/hotels/meals. Testimony begins at 1:34 (one hour, 34 minutes). The meeting was nearly 20 hours over two days. On this second video, at the end, you will see two women who are the FDA Patient Representative (Barbara Berney) and the FDA Consumer Representative (Connie Whittington) who are paid and hand selected by FDA to represent our interests.
It is instructive to confirm that the realization of harm came from foreign countries that had registries! Medical device companies continued to market devices for years though there was evidence of their harm and ineffectiveness. FDA was late in stepping in.
PHILADELPHIA — Generic competition — a billion-dollar problem for brand-name drug companies since the 1980s — is making inroads in the orthopedic medical devices industry. Last week Cardinal Health Inc., one of the three biggest device wholesalers, said it was increasing its offering of lower-cost products for broken bones.
This nascent trend, borne of increasing pressure to control health care costs, represents a direct threat to brand-name device makers such as West Chester, Pa.-based Synthes, which was bought in June by Johnson & Johnson for $19.7 billion.
Cardinal Health, 21st on the Fortune 500 list, is based in Dublin, Ohio. In announcing its so-called "Orthopedic Solutions" option for hospitals and surgery centers, Cardinal said it could supply some products at 30 to 50 percent savings.
"Based upon our market and customer research, we believe that U.S. health care providers are ready to support a simpler, more transparent, fair priced orthopedic business model," Cardinal Health executive Lisa Ashby said in a statement.
Cardinal Health entered a partnership with Emerge Medical, a Denver-based company that makes surgical screws, drill bits and guide wires. Emerge CEO John Marotta is a former Synthes sale representative. Synthes was sufficiently annoyed with his efforts that it sued him in 2011. He has countersued, and a trial is pending.
"Together we will provide a low-cost trauma solution that will drive simplicity and transparency to this pressured health care environment," Marotta said of the Cardinal Health partnership.
The U.S. Food and Drug Administration does not use the term "generic" devices, as it does with drugs, but there is an approval process. Like drugs, medical devices have patents, and the disputes employ numerous lawyers.
Johnson & Johnson CEO Alex Gorsky said last week that medical devices are a $40 billion market worldwide. But Johnson & Johnson, like other device makers is being pressed to lower prices or at least slow the rate of growth.
Trade publication Orthopedic Network News reported that list prices for hip and knee implants increased 4.2 percent between 2011 and 2012 — the lowest increase in the 19 years it has surveyed device manufacturers and the fourth straight decline in the growth rate.
Laura Ruth, director of the health care practice for research and consulting firm Fuld & Co., said the generic device market is still "fragmented," but pointed to a January report by the Government Accountability Office as an example of greater scrutiny of the cost and acquisition process of hospitals, whose bill are often transferred to taxpayers. Hospitals often buy through group purchasing organizations, which have been criticized for being too cozy with manufacturers and too secretive with hospitals.
It is very disturbing yet essential that Robert M. Wachter, MD, Professor and Associate Chair of the Department of Medicine at the University of California, San Francisco and chief of the medical service at UCSF Medical Center must communicate to the public about the epidemic of hospital errors.
In addition to the lack of accountability of hospitals and an increase in errors at for-profit hospitals, there is a parallel in the medical device industry. Joint replacement is the #1 expenditure of Medicare, yet we learn of the devastating failure of metal-on-metal hips from foreign registries after tens of thousands of implants and revisions have taken place.
The FDA charter does not legally require surgeons to report device failures unless there is a fatality. 510(k) approvals allow untested devices to be implanted with no independent post-market follow up. Patient harm is not acknowledged and therefore the patient harm continues unabated. The industry gets more profitable and powerful and potentially more destructive of limited public healthcare funding.
The cries to protect industry jobs and threats that the industry will abandon the U.S. to profit overseas would not be necessary if the products were actually safe and effective, as advertised.
Although it was mentioned how in some cases "mistakes" are made for the sake of profits, it was not said that many well intentioned health care providers cannot report these systems due to gagging clauses in their contracts.
Those who report issues to their upper levels many times face hostility and have to leave their jobs.
Is about time to lobby for legislation that protects "whistle blowers" on issues of safety and negligent practices. Including cancellation of "non compete" clauses on their contracts when they have to leave their jobs after reporting their institution/employer.
The audio link to the People's Pharmacy is here!
Your three action items are in RED. You must go to the Mayo website (live link provided!) to vote-this is just a tutorial on this page.
Editor's Note: Joleen C. is a patient/caregiver who submitted the following essay as part of the Mayo Clinic Center for Social Media Patient, Caregiver Scholarship Contest. To vote, simply use the Facebook "Like" or Twitter "Tweet" buttons at the bottom of each post to share or leave a positive comment. The top vote-getters will be finalists.
Login, "Like" Twitter & Post: When the Medical Device Safety Act is passed by Congress and the Charter of the FDA is amended to include voting Patient Representatives on the medical device panel (as in pharmaceuticals), social media will be able to claim a large part of the victory.
Four years ago I began handling phone, mail and other correspondence for a family member who experienced early failure of a joint replacement implant. Internet research revealed the medical and legal purgatory of thousands of joint replacement implant patients. Navigating the medical system (for a disabled person prescribed maximum dose painkiller and living 1,000 miles apart) is challenging but not uncommon situation for many caregivers, I learned. Because the root of the problem was intractable (poor federal public policy) my role transitioned to unpaid full-time advocate. I applied and was selected in September 2010 to attend the FDA Patient Representative workshop, which expanded my advocacy to all patients with failed implanted medical devices.
My stated goal is to help patients with failed devices access the medical care that they require and to work toward the conclusions of the Institute of Medicine's 7/29/2011 report. It advised the FDA to restrict the use of FDA 510(k) approvals for implanted devices and provide a post-market UDI national registry that would be accessible to patients and their medical providers.
This quest prompted me to join with a number of effective advocacy organizations such as The Society for Preventative Medicine, Consumers Union and SpeakerLink. I created a blog (http://fida-advocate.blogspot.com) and regularly participate on FaceBook, Twitter (@JjrkCh) and LinkedIn. I have testified twice at FDA/CDRH Town Hall meetings and have traveled from my home in Dallas, TX to Minnesota, Washington, DC -4 times-, San Francisco, CA, Irving & San Antonio & Austin, TX in my role as advocate. Recently, financial limitations prevented me from attending Regina Holliday's The Walking Gallery and the HDI Forum in Washington, D.C. (both with registration complete) so I participated virtually on a webinar.
In my work toward the goal of safer and more effective implant devices I would value and benefit from discussions with trained social media professionals and other advocates. I wish to elevate my advocacy skills and clarity of purpose so that I capably represent the patients who have been harmed and are often unable to travel or spare time/money for this endeavor. Exposure to new ideas/attitudes would refresh and enhance my implementation of more targeted social media communications. My advocacy includes educating the public, the device industry, administrators and legislators about federal public policy and legislative changes that would strengthen patient safety and reduce patient harm.
Select TWEET button. Select 'LIKE' button.
Read to the bottom of all comments and leave your COMMENT and press POST COMMENT.
Please vote daily until August 4, 2012.
Your vote is very valuable to me. All it takes is a daily quick positive comment and clicks on the "like" and/or "tweet" button at the bottom of my essay page.
Registration costs $1200 (not including travel/lodging/meals) so most patients/caregivers and patient advocates cannot afford to attend.
Contest ends August 4, 2012.
Help me win a Mayo scholarship!
Go to http://bit.ly/PakhxV To vote: Like, Tweet and a positive comment-daily! Thx!
CHICAGO (Reuters) - Johnson & Johnson faces a potentially more damaging and costly sequel to the $3 billion recall of its ASR all-metal artificial hips two years ago, one of the most expensive medical device failures in U.S. history.
A successor to ASR, the Pinnacle metal-on-metal hip system has nearly 1,600 lawsuits pending in U.S. courts. Doctors who are tracking large groups of patients with both products estimate that more than 10 percent of the Pinnacle all-metal hips will have failed in the next two to three years.
Metal-on-metal hip implants were sold on being more durable than those made of other materials, such as polyethylene or ceramic. They are meant to last up to 15 years, but as controversy over all metal-on-metal implants heats up, fewer surgeons are using them.
A survey taken by the American Academy of Orthopaedic Surgeons in 2010 showed 16 percent of surgeons were using metal-on-metal implants before the U.S. Food and Drug Administration warned of potential problems. That number dropped to 10 percent since the FDA warning, and doctors say the number probably has dwindled further.
Many patients with the Pinnacle metal-on-metal device are experiencing the same problems as those who got the ASR product, including pain and swelling, limited mobility, and dislocation. Perhaps most concerning, some doctors say, is the high levels of cobalt and chromium in the bloodstream resulting from wear of the all-metal implants. Metallosis, as it is known, can lead to cardiovascular, neurological, renal and thyroid problems, in addition to destroying soft tissue, muscle and bone.
"We're simply seeing the tip of the iceberg with metal-on-metal failures," Dr Mary O'Connor, an orthopedic surgeon at the Mayo Clinic in Jacksonville, Florida, said of the entire class of metal-on-metal devices. O'Connor said she does not use metal-on-metal hip implants because she has been concerned about metal poisoning for years.
The new round of complaints represents a significant threat for J&J's DePuy Orthopedics unit, whose Pinnacle line includes non-metal models and covers a much wider range of products than ASR. The diversified healthcare giant, under new Chief Executive Alex Gorsky, has also just raised its bet on orthopedic products with the $20 billion purchase of device maker Synthes.
"Litigation is what it is, but the ASR is a very different system and has a very different design and has very different clinical performance" than the Pinnacle, said Mindy Tinsley, a spokeswoman for DePuy. "We recalled it because it was not performing as it should."
She said DePuy is closely monitoring the performance of the Pinnacle metal-on-metal system, but is "very confident" in the product and will vigorously defend itself against lawsuits. DePuy did not make other executives available for comment.
DePuy and FDA officials said there is not sufficient evidence linking metal ions in the blood to health risks.
A total of 500,000 patients in the United States have received metal-on-metal hips, according to government data. Of those patients, an estimated 150,000 received the Pinnacle device, and 37,000 got the ASR implant. But while J&J has set aside $3 billion to settle the 3,000 ASR lawsuits, it is fighting complaints related to the Pinnacle device -- meaning that patients with virtually identical problems are facing different financial burdens.
Frances Grisham, 50, from Jackson, Tennessee, recently had surgery to repair a fracture to her left hip caused by the ASR implant. She was reimbursed for most of her out-of-pocket expenses and could be eligible for some of the settlement funds.
Harriett Bowen, 64, from Salisbury, Maryland, received the Pinnacle all-metal hip in 2008. She soon developed the same symptoms as Grisham: pain, limited mobility and elevated levels of cobalt and chromium in her blood. In July 2011, Bowen's left hip fractured at the implant site, requiring more surgery.
Bowen's doctor determined she had a cobalt and chromium count of 7 micrograms per liter (mcg/L), a level flagged by UK health authorities as worrying. "He said, 'Look, we've got to get this thing out of you.' It nearly scared me to death."
Unlike Grisham, she has received no compensation for the repair from J&J. Bowen is suing J&J.
"I have never done anything like this before, but considering what I went through for three years, I feel like I should be compensated," said Bowen.
While other makers of total hip replacement systems -- including Smith & Nephew, Zimmer Holdings, Wright Medical and Biomet Inc -- face similar complaints, the numbers of devices involved is much smaller. The next most widely used product belongs to Biomet, which is defending itself against lawsuits over its metal-on-metal M2a Magnum Hip System.
Legal experts say J&J is taking a harder line defending itself against Pinnacle metal-on-metal claims, hiring a top product liability defense firm and refusing to recognize patient complaints or pay for replacing the hip devices - known as revision surgery. It maintains the device performs better than other all-metal hip implants.
Paul Voorhorst, director of biostatistics and data management at DePuy, told an FDA advisory panel last month that the Pinnacle metal-on-metal device "is performing consistent with or better than other metal-on-metal products."
Should the Pinnacle lawsuits be found to have merit, J&J could end up paying nearly $5 billion to cover revision surgeries alone, according to plaintiff attorneys. DePuy revenue last year was $5.81 billion, or 9 percent of J&J's total.
Legal experts not involved in the cases say J&J probably is just taking its chances to see how the first few lawsuits play out - a common strategy for Big Pharma in major drug litigation cases. They say J&J may be aided in its defense by the lack of any U.S. program to track the performance of medical devices once they are implanted in people's bodies.
"The last thing plaintiff lawyers want is to go one by one (for each case). With so much unknown, proving cause and effect may be difficult," said Carl Tobias, Williams professor of law at the University of Richmond School of Law.
Cindy Schipani, professor of business law at the University of Michigan, said J&J could be playing with fire if the Pinnacle metal-on-metal devices are shown to be defective.
"They lose credibility if they keep saying they're not responsible and then it turns out the product is the problem," she said. "I question this strategy."
While doctors can report problems about the Pinnacle to an FDA database, products with that name also include artificial hips that are not exclusively made of metal. One product is metal-on-polyethylene, the most popular of the Pinnacle devices, and another is metal-on-ceramic. A Reuters search of the database could not isolate adverse events reported for the all-metal Pinnacle, which is the least used of the Pinnacle products.
There is also no hard data yet on the Pinnacle's failure rate, partly because DePuy does not publicly disclose how many were implanted. DePuy's Voorhorst told the FDA advisory panel that 4 percent to 4.5 percent of these Pinnacle implants require a second surgery to fix the devices within five years after implantation, which is in line with other hip devices.
Felecia Stern, an attorney with Bernstein Liebhard LLP, represents Bowen, Grisham and many other patients who received the ASR and Pinnacle all-metal devices. She noted that the recall of 93,000 ASR implants in 2010 led doctors to notify patients and monitor for high metal levels. But problems with the Pinnacle are being reported less systematically since the devices weren't pulled from the market.
"At the end of the day we will see a similar occurrence of high metal levels in Pinnacle metal-on-metal recipients as more and more of them get their blood tested. That is certainly what we are seeing in our client population," she said.
Her firm also serves on the Plaintiffs Steering Committee for the federal Pinnacle lawsuits, which have been consolidated into a multi-district litigation in Texas.
The FDA has been monitoring problems with all-metal hip implants and convened the panel of outside advisers last month to discuss their safety. The panel concluded there was little reason for surgeons to use these devices given the risks.
In May 2011, the agency ordered device makers to conduct follow-up studies in cases in which an implant's failure could have serious consequences. Companies would be expected to take blood samples from patients to measure metal ion levels. But more than a year later, the FDA and device manufacturers agreed on study protocols for less than one quarter of the devices. Most of the study plans, including DePuy's, have not been finalized.
"We need more data to better understand how these devices perform," FDA spokeswoman Michelle Bolek said. "We are open to a more collaborative effort, if it helps us get the data we need."
The final failure rate for the ASR device has not yet been established, but a study released last March by the British Orthopaedic Association and the British Hip Society indicated a failure rate of up to 49 percent after six years - nearly four times the rate cited by DePuy when it recalled the device.
Dr David Langton is an orthopedist who has studied all-metal implants for years and supplied the two British organizations with data. He said he expects the ASR failure rate to rise to 80 percent at eight years. Based on a cohort of about 1,000 patients he is tracking at North Tees Hospital in the UK, the Pinnacle metal-on-metal hip has a failure rate of 8 percent at five years. He said that rate climbs to 16 percent after 6-1/2 years.
About 150,000 Pinnacle metal-on-metal devices are estimated to be implanted in patients outside the United States.
Several differences between the ASR and Pinnacle metal-on-metal could explain a lower failure rate.
One main reason is that the Pinnacle has a smaller head; larger heads are associated with higher failure rates because there is more friction.
Langton believes it is just be a matter of time before Pinnacle all-metal device failure rates climb, as more metal debris from the implant are released into the bloodstream and tissue. And while the failure rate might be lower than ASR, the absolute number of patients is higher.
"We believe the (Pinnacle) failure rate will be far above 10 percent," said attorney Brian Devine of Seeger Salvas LLP, which is handling both ASR and Pinnacle cases.
That would translate into second replacement surgery for 15,000 patients, he said. In 2002, Sulzer Medica AG paid an average of $250,000 per revision on its 2001 recall of its InterOp hip. Adjusting for inflation, an average J&J settlement could be $319,000 per revision, or $4.785 billion in total, he said.
Mayo Clinic's O'Connor is worried that the entry of metal ions into the bloodstream will damage internal organs, not just the surrounding tissues in the hip socket. There are also concerns high ion levels cause cancer, though that has not been proven.
"Autopsy studies of patients with metal-on-metal implants showed metal ions were everywhere the body - in the liver, the spleen, all over the place," O'Connor said.
Letting Big Pharma Review Its Own Drugs — What Could Go Wrong?
We can't trust drug companies to disclose product safety hazards when they stand to gain so much from fudging the facts.
When British drugmaker GlaxoSmithKline (GSK) agreed to pay $3 billion in criminal and civil fines for illegal marketing of several drugs and hiding safety from the U.S. Food and Drug Administration (FDA), it probably seemed to many people like fitting punishment. It's the largest fine ever levied against a pharmaceutical company, and the civil and criminal charges against GSK included marketing its antidepressants Paxil and Wellbutrin for unapproved (read: unproven) uses, giving Medicaid false information about prices it was charging for the drugs, and failing to report patient safety data about diabetes medication Avandia to the FDA. But even $3 billion is probably not going to get GSK to change its ways -- and fines do virtually nothing to protect patients.
When it submitted false price information to Medicaid, GSK was harming taxpayers, a financial crime that is amply repaid by the $300 million the company is paying for that offence. But discouraging future bad behavior is a different story, because GSK is one of the world's biggest drug makers, with annual revenue of more than $40 billion. A $300 million fine starts to look like just the cost of doing business when spread over the period of time when the company was bilking Medicaid.
Fines are even less effective when it comes to preventing patients from being physically harmed. GSK is accused of illegally marketing two antidepressants -- Paxil for depression in adolescents, and Wellbutrin for weight loss, substance addiction, ADHD and other problems. Paxil has been shown to have significant side-effects, including triggering suicidal thoughts and behavior in some patients, and neither antidepressant is much more effective than a sugar pill in the vast majority of patients with depression. Fining the company after the fact doesn't do much for the patients who have already been hurt by their marketing practices.
That's even more the case for GSK's egregious behavior regarding its diabetes drug Avandia. When a new drug comes on the market, sometimes the FDA will ask or require that the manufacturer to do a study, called a post-marketing trial, to look for rare side effects and establish whether the drug is safe over the long term. That's important because often the clinical trials that are done before a drug is approved aren't big enough, and don't last long enough, to say whether a drug is safe to use over a long period.
With Avandia, GSK fudged the results of those post-marketing trials. The company claimed that its RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes) trial showed no evidence that Avandia caused heart attacks or other cardiac diseases. But when outside researchers looked at the data they found massive irregularities and plenty of cases of harm, including patients who died and then mysteriously disappeared from the clinical trial records.
GSK hasn't admitted anything more than "inadvertently" failing to inform the FDA of problems, and the fine isn't going to protect patients from future Avandias. What we really need is a better system for tracking drugs once they are on the market.
Right now, we leave this crucial task to the very companies that have every reason to fudge data, ignore problems -- even deaths -- and keep doctors and patients in the dark, because they are making too much money to do otherwise. At its peak, Avandia earned GSK $2.2 billion a year. It was a phenomenally lucrative drug. The $250 million levied against the company for that part of the fine amounts to less than a slap on the wrist.
The solution isn't stiffer punishments for fraud -- we should take away the power to do harm in the first place. That means we need to stop giving drug companies the opportunity to sell out patient safety in exchange for another few months or years on the market. The simplest way to do that is to have automatic, external post-market surveillance for all new drugs.
Any new drug should be considered by both patients and doctors to be experimental for the first few months, or even years it is on the market, and the FDA should treat the approval of the drug as provisional. (The same goes for new medical devices.) For at least two years, any patient who might receive a new drug or medical device has to be fully informed of its known side effects, and of its experimental status. Data on those patients should be tracked (anonymously), and compared to patients receiving other treatments. Most importantly, automatic algorithms can search those data for patterns revealing any negative effects of the new product, so safety problems can be caught quickly.
Perhaps most importantly, it would force us to admit that we don't truly know that our treatments are safe when we start using them -- and that would give patients a chance to be more informed about their choices. That seems like a better system that letting companies kill patients, and then pretending to fix the problem by slapping them with fines every few years.
SHANNON BROWNLEE & JOE COLUCCI - Shannon Brownlee is the acting director of the health policy program at the New America Foundation. She has written previously for The Atlantic, New York Times Magazine, and The New Republic, among others. Joe Colucci is a research associate in the New America Foundation's Health Policy Program and editor of the program's New Health Dialogue blog.
Criminal prosecutions more effective deterrent.
FDA Tracking Implantable Devices Soon!


text:
Hot Press, January 22, 1982
Revision as of 15:09, 22 August 2017 by Zmuda (Talk | contribs) (+UK & Irish magazines index)
75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22
UK & Ireland music weeklies
UK & Ireland magazines
UK & Ireland newspapers
US rock magazines
US music magazines
US alternative weeklies
European magazines
Canada • Mexico • Asia
Australia • New Zealand
South America • Africa
Blogs • Fanzines • Books
Hot Press
1982 February 5
UK & Irish magazines index
Hot Press, January 22 - February 4, 1982
EC is featured in the 1981 recap and 1982 preview.
HotPress.com
Wikipedia: Hot Press
Retrieved from "http://www.elviscostello.info/wiki/index.php?title=Hot_Press,_January_22,_1982&oldid=17368290"
Bibliography 1982
Article needed


On this edition of the Weekly Before & After, we focus on a hollow ring that was very damaged and misshapen. Hollow rings are very challenging for repairs because they have no structure in place to work with.
I have a ring which has a gap in the back – in other words the band doesn't connect all the way around. This is a silver ring and it has sentimental value for me. The size is 7.5 with the gap and I would like to keep the ring that size. Do you do these alterations and if so, what is the cost?
Hey Susanne, thank you for reaching out to us! We can definitely help with modifying the band on your silver ring. The process would be to replace the area of the band that has the gap instead of filling it in, and the cost would depend how much of the band (shank) needs to be replaced. Could you please message us at info@myjewelryrepair.com so we can understand the details of your particular ring? Thanks again!


text:
//=================================================================================================

//=================================================================================================

#ifndef _BLAZE_SYSTEM_WARNINGDISABLE_H_
#define _BLAZE_SYSTEM_WARNINGDISABLE_H_

//=================================================================================================
//
//  MICROSOFT VISUAL STUDIO WARNINGS
//
//=================================================================================================

#if defined(_MSC_VER) && (_MSC_VER >= 1400)

   // Disables a 'deprecated' warning for some standard library functions. This warning
   // is emitted when you use some perfectly conforming library functions in a perfectly
   // correct way, and also by some of Microsoft's own standard library code. For more
   // information about this particular warning, see
   // http://msdn.microsoft.com/en-us/library/ttcz0bys(VS.80).aspx
#  pragma warning(disable:4996)

   // Disables a warning for a this pointer that is passed to a base class in the constructor
   // initializer list.
#  pragma warning(disable:4355)

   // Disables the warning for ignored C++ exception specifications.
#  pragma warning(disable:4290)

#endif

//=================================================================================================
//
//  INTEL WARNINGS
//
//=================================================================================================

#if defined(__INTEL_COMPILER) || defined(__ICL)

   // Disables a 'deprecated' warning for some standard library functions.
#  pragma warning(disable:1786)

#endif

#endif


Summary: Companies must expand their clawback policies once new rules are enacted by the Securities and Exchange Commission.
Although it was signed into law nearly five years ago, the Dodd-Frank Wall Street Reform and Consumer Protection Act still contains gaps throughout its text, according to CorpCounsel.com. The U.S. Securities and Exchange Commission is still working to fill in parts of the law, and, recently, it worked to provide additional clarity on "clawbacks" of executive compensation.
Last year, the SEC examined the how cyber attacks may threaten Wall Street.
The proposed rules expand the scope of individuals who may have part of their compensation taken away if the company issues an accounting restatement. The rules must go through a 60-day comment period and an additional commission vote, companies should begin thinking about how they will respond to these changes.
The proposal passed 3-2 in the most recent vote. According to the National Law Review, "incentive-based compensation" subject to clawback is any compensation that is granted, earned, or vested based either entirely or in part on the attainment of a financial reporting measure.
In 2009, Dewey settled a clawback suit.
The standards create a new penalty for companies that are listed on SEC exchanges: incentive-based executive compensation that is tired to accounting-related metrics, total shareholder, or stock price may be clawed back if the company has to modify its financial statements. Companies must take back the difference between what the pay was with inaccurate statements and what it would be with the accurate statements.
All companies that are covered by the proposed rule will have to file their clawback plans with the SEC and include additional information, such as the names of executives who did not have compensation clawed back with the reasons why.
Most publicly traded companies have been required to have clawback policies under the Sarbanes-Oxley Act of 2002. Some have enhanced their requirements beyond what SOX requires, but it is likely that most companies will have to complete additional work on their policies now that the plans have been announced by the SEC.
Regina Olshan, a partner at Skadden, Arps, Slate, Meagher & Flom said, "I'd be surprised if there are many policies out there that don't have to be revised." Olshan is also the global head of the firm's executive compensation and benefits group.
Last year, HP agreed to settle embezzlement, tax evasion, and bribery charges brought by the SEC for $108 million.
A significant change to the rules is how far back in time the claws may reach. SOX only required compensation to be taken back for one year after the accounting misstatement. The new rules will go back three years before the restatement was issued. However, the New York Times noted that if the cost of pursuing the executive would exceed any amount the company may recover, reclaiming a bonus may not be required.
Do you think the new regulations are a good idea?
Another major change is that there will be an expansion in the type of executives who may have their compensation taken back. Under SOX, only the chief executive officer and the chief financial officer were eligible for clawbacks. Now, the principal accounting officer; vice presidents in charge of principal business units, divisions or functions; and others who perform policymaking functions for a company may be eligible.
SEC guidance seeks comments on whether chief legal officers should be named in these recovery policies, so the issue will eventually be addressed. Even if CLOs remain ineligible for clawbacks, companies will still need to address their organization charts to examine who may be subject to clawbacks and then use this study to create and enforce a compliant compensation recovery policy.
Markel added that those boards that wish to reduce the threat of clawbacks should consider changes to how executives are compensated. "I think it could be an inflection point," she noted. A model based on discretionary pay may protect executives from such risks, for example.


text:
Q: Visual Basic not writing to SQL backend I am having trouble figuring out why my updates and inserts aren't writing to SQL Server backend. I do not have much visual basic experience and am wondering if anyone can point me in the right direction.
Protected Sub CatNutritionTypes_RowUpdating(ByVal sender As Object, ByVal e As GridViewUpdateEventArgs)
        Try

            Using sqlCon As SqlConnection = New SqlConnection(Azure_Connection_String)
                sqlCon.Open()
                Dim query As String = "UPDATE Norm.CAT_Nutrition_Types SET Genesis_NutrientKey=@Genesis_NutrientKey, CAT_UOMID=@CAT_UOMID, IsViewable=@IsViewable, IsDailyValue=@IsDailyValue, IsCalculated=@IsCalculated, IsUserCreated=@IsUserCreated, CAT_Nutrient_Group_ID=@CAT_Nutrient_Group_ID, Genesis_API_GUID=@Genesis_API_GUID, EnteredDateTime=@EnteredDateTime, UserID=@UserID, IsDeleted=@IsDeleted, DeletedDateTime=@DeletedDateTime, IsRequired=@IsRequired, OrderBy=@OrderBy, Percent_Diff=@Percent_Diff  WHERE CAT_Nutrition_TypesID = @id"
                Dim sqlCmd As SqlCommand = New SqlCommand(query, sqlCon)
                sqlCmd.Parameters.AddWithValue("@Genesis_NutrientKey", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtGenesisNutrientKey"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@Nutritional_Desc", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtNutritionalDesc"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@AbbreviatedName", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtAbbreviatedName"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@CAT_UOMID", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtCatUomId"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@IsViewable", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtIsViewable"), CheckBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@IsDailyValue", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtIsDailyValue"), CheckBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@IsCalculated", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtIsCalculated"), CheckBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@IsUserCreated", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtIsUserCreated"), CheckBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@CAT_Nutrient_Group_ID", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtCatNutrientGroupId"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@Genesis_API_GUID", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtGenesisApiGuid"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@EnteredDateTime", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtEnteredDateTime"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@UserID", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtUserId"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@IsDeleted", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtIsDeleted"), CheckBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@DeletedDateTime", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtDeletedDateTime"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@IsRequired", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtIsRequired"), CheckBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@OrderBy", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtOrderBy"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@Percent_Diff", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtPercentDiff"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@id", Convert.ToInt32(CatNutritionTypes.DataKeys(e.RowIndex).Value.ToString()))
                sqlCmd.ExecuteNonQuery()
                CatNutritionTypes.EditIndex = -1
                PopulateGridview()
                lblSuccessMessage.Text = "Selected Record Updated"
                lblErrorMessage.Text = ""
            End Using

        Catch ex As Exception
            lblSuccessMessage.Text = ""
            lblErrorMessage.Text = ex.Message
        End Try
    End Sub

Protected Sub CatNutritionTypes_RowCommand(ByVal sender As Object, ByVal e As GridViewCommandEventArgs)
    Try

        If e.CommandName.Equals("AddNew") Then

            Using sqlCon As SqlConnection = New SqlConnection(Azure_Connection_String)
                sqlCon.Open()
                Dim query As String = "INSERT INTO Norm.CAT_Nutrition_Types (Genesis_NutrientKey, Nutritional_Desc, AbbreviatedName, CAT_UOMID, IsViewable, IsDailyValue, IsCalculated, IsUserCreated, CAT_Nutrient_Group, Genesis_API_GUID,  EnteredDateTime, UserID, IsDeleted, DeletedDateTime, IsRequired, OrderBy, Percent_Diff) VALUES (@Genesis_NutrientKey, @Nutritional_Desc, @AbbreviatedName, @CAT_UOMID, @IsViewable, @IsDailyValue, @IsCalculated, @IsUserCreated, @CAT_Nutrient_Group, @Genesis_API_GUID,  @EnteredDateTime, @UserID, @IsDeleted, @DeletedDateTime, @IsRequired, @OrderBy, @Percent_Diff)"
                Dim sqlCmd As SqlCommand = New SqlCommand(query, sqlCon)
                sqlCmd.Parameters.AddWithValue("@Genesis_NutrientKey", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtGenesisNutrientKeyFooter"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@Nutritional_Desc", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtNutritionalDescFooter"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@AbbreviatedName", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtAbbreviatedNameFooter"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@CAT_UOMID", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtCatUomIdFooter"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@IsViewable", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtIsViewableFooter"), CheckBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@IsDailyValue", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtIsDailyValueFooter"), CheckBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@IsCalculated", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtIsCalculatedFooter"), CheckBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@IsUserCreated", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtIsUserCreatedFooter"), CheckBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@CAT_Nutrient_Group_ID", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtCatNutrientGroupIdFooter"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@Genesis_API_GUID", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtGenesisApiGuidFooter"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@EnteredDateTime", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtEnteredDateTimeFooter"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@UserID", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtUserIdFooter"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@IsDeleted", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtIsDeletedFooter"), CheckBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@DeletedDateTime", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtDeletedDateTimeFooter"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@IsRequired", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtIsRequiredFooter"), CheckBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@OrderBy", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtOrderByFooter"), TextBox)).Text.Trim())
                sqlCmd.Parameters.AddWithValue("@Percent_Diff", (TryCast(CatNutritionTypes.FooterRow.FindControl("txtPercentDiffFooter"), TextBox)).Text.Trim())
                sqlCmd.ExecuteNonQuery()
                PopulateGridview()
                lblSuccessMessage.Text = "New Record Added"
                lblErrorMessage.Text = ""

            End Using
        End If

    Catch ex As Exception
        lblSuccessMessage.Text = ""
        lblErrorMessage.Text = ex.Message
    End Try
End Sub


text:
Josh Fitzwater
We're Hiring: Creative Project Coordinator
Holden Ellis, a creative marketing agency, seeks a Creative Project Coordinator that's equal parts detail freak and creative geek to help coordinate and manage projects as well as communicate directly to clients regarding status and performance of projects and campaigns. Our ideal team member uses their Type-A powers for good to keep us moving forward on-time, on-budget and on-awesome. Think it's you? Prove it.
What in Tarnation is Content Marketing?
Web is the engine. Content is the fuel. It's time to combust.
Lindsey Son
Twitter Links and Photos Won't Count in ...
If you haven't already heard, Twitter just gave you a reason to celebrate—by planning to exclude links, photos and GIFs (which are now searchable on Twitter) in its 140-character limit. On Monday, Bloomberg reported that this is supposed to go into effect within the next couple of weeks. It's a game-changer. With links alone, you get 23 characters (even after Twitter shortens a link). Twenty-three more characters, PLUS a photo or GIF?
We're Hiring a Content Copywriter
Mark Twain said, "The difference between the almost right word and the right word is really a large matter—it's the difference between the lightning bug and the lightning." If this lights a fire under your butt, then upload that resume, cover letter and hit SEND to josh@holdenellis.com.
Pizza Party Planning 101
When it's National Pizza Party Day, there's only one thing on our mind—the cheesy, doughy deliciousness we call pizza (or 'za if you're a Phil Dunphy fan). You just cannot go wrong with bread, cheese and marinara (plus your choice of endless toppings). So, how do we throw a pizza party at Holden Ellis?
Twitter Links and Photos Won't Count in 140-Character Limit
Instagram's New Makeover is NOT that Bad
Out with the Old, In with the New
Instagram updated its logo and switched to a black-and-white interface on Wednesday, and naturally, the Internet freaked out. Change is inevitable, but Instagram users aren't having it. To them, this new makeover is like a 'Before & After' gone totally wrong.
The Neuroscience of Digital Storytelling
The digital marketing game is rooted in providing content that makes your specific audience's life better. It answers a question they might have or provides insight into some kind of empathy or emotional trigger. But why is it that digital storytelling can move mountains for your brand, audience and bottom-line?
How to Create the Video Your Business Actually Needs
Tell A Story (but not about you)
News flash: You are not the center of the universe. And sadly, neither is your company. Make the story about your audience not about you. When the focus of your message is self-congratulatory you turn into Big Brother who needs no help and is out of touch with it's own constituents. The reason why the content storytelling games works is because of its bigger picture lens—not because of how great YOU are. It's because of how great the PEOPLE who've walked through your doors are.
Confessions from an Ex-Social Media Director: 5 Tips for Using Facebook for Small Business
"Forgive me, Mark, for I have sinned."
As a small business owner in Columbus, Ohio (HQ for Holden + Ellis) or elsewhere, you've probably muttered something along these lines whilst trying to generate business or leads via Facebook. A lot of professionals say you just need to be "authentic" and "real," which is true, but that doesn't make success any easier. In fact, it seems counterintuitive, but being authentic with content and message is incredibly difficult and complicated. It takes a shitload of discipline. I've spent most of career helping businesses and organizations do just that.
Top 3 Columbus SEO Strategies for Every Business
Big or small, every Columbus-based company should be utilizing SEO not just for Google page rankings (which of course, being on page one is the equivalent to being named Prom King or Queen), but also it's about using organic search to find qualified visitors and nurturing them through your goals. Here are a few "gotta-do's" that we recommend to jump-start your Columbus SEO:
Holden Ellis | A Columbus Digital Marketing Agency
11 East Gay Street, Unit 402, Columbus, Ohio 43215 | 614.313.0151 | josh@holdenellis.com
Holden Ellis is proud to be an equal opportunity employer